Advances in the Action Mechanism of Classical Pathways IKKα and IKKβ in Hematological Tumors and Drug Therapy Blocking Their Effect--Review.
10.19746/j.cnki.issn.1009-2137.2021.01.052
- Author:
Xiao-Ting LIU
1
;
Gao-Feng JIANG
2
;
Wei-Qi HUANG
2
;
Yong-Ming ZHOU
3
Author Information
1. Department of Hematology，Tianyou Hospital Affiliated to Wuhan University of Science and Technology, Wuhan 430064, Hubei Province ,China.
2. Central Laboratory，Tianyou Hospital Affiliated to Wuhan University of Science and Technology, Wuhan 430064, Hubei Province ,China.
3. Central Laboratory，Tianyou Hospital Affiliated to Wuhan University of Science and Technology, Wuhan 430064, Hubei Province ,China,E-mail:zhym112@126.com.
- Publication Type:Review
- MeSH:
Cell Survival;
Hematologic Neoplasms;
Humans;
I-kappa B Kinase/metabolism*;
NF-kappa B/metabolism*;
Signal Transduction;
Tumor Necrosis Factor-alpha
- From:
Journal of Experimental Hematology
2021;29(1):306-310
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, it is found that the classical IKKα and IKKβ pathway were closely relates with hematological tumors, except the classical pathogenesis, moreover the classical IKKβ pathway is deeply studied. The studies indicated that the IKKβis activated to phosphorylate the NF-κB through multiple cascades under the effect of extracellular IL-6, TNF-α and other stimulating factors. At the cellular level, the classical IKKβcan promote the tumor cell survival and proliferation, reduce the cell apoptosis, and promote the angiogenesis and cell transfer. Although the classical IKKα plays a role in regulating IKKβ activity, but its role in non-classical pathway is more prominent. This review briefly summarizes the latest advance of researches on the pathogenesis of hematological malignancies in term of IKKα and IKKβpathway, so as to provide the theoretic basis for deeply understanding and studying the pathogenesis of hematologic tumors. At present, blocking the classical IKKα and IKKβ pathway has become a new target for treatment of hematological tumors, moreover, some specific inhibitor for IKKα and IKKβpathway have been developed, for example, LY2409881, BMS 345541 and so on. Most of these drugs are in clinical trials and display some good anti-tumor effects.
